107 related articles for article (PubMed ID: 17387689)
21. In vitro evidence that an aqueous extract of Centella asiatica modulates α-synuclein aggregation dynamics.
Berrocal R; Vasudevaraju P; Indi SS; Sambasiva Rao KR; Rao KS
J Alzheimers Dis; 2014; 39(2):457-65. PubMed ID: 24284367
[TBL] [Abstract][Full Text] [Related]
22. Fibrillogenic and non-fibrillogenic ensembles of SDS-bound human alpha-synuclein.
Ahmad MF; Ramakrishna T; Raman B; Rao ChM
J Mol Biol; 2006 Dec; 364(5):1061-72. PubMed ID: 17054982
[TBL] [Abstract][Full Text] [Related]
23. Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein.
Kobayashi M; Kim J; Kobayashi N; Han S; Nakamura C; Ikebukuro K; Sode K
Biochem Biophys Res Commun; 2006 Oct; 349(3):1139-44. PubMed ID: 16962995
[TBL] [Abstract][Full Text] [Related]
24. Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity.
Takahashi R; Ono K; Takamura Y; Mizuguchi M; Ikeda T; Nishijo H; Yamada M
J Neurochem; 2015 Sep; 134(5):943-55. PubMed ID: 26016728
[TBL] [Abstract][Full Text] [Related]
25. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
[TBL] [Abstract][Full Text] [Related]
26. Docosahexaenoic acid disrupts in vitro amyloid beta(1-40) fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats.
Hashimoto M; Shahdat HM; Yamashita S; Katakura M; Tanabe Y; Fujiwara H; Gamoh S; Miyazawa T; Arai H; Shimada T; Shido O
J Neurochem; 2008 Dec; 107(6):1634-46. PubMed ID: 19014387
[TBL] [Abstract][Full Text] [Related]
27. Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro.
Ono K; Hasegawa K; Naiki H; Yamada M
Biochim Biophys Acta; 2004 Nov; 1690(3):193-202. PubMed ID: 15511626
[TBL] [Abstract][Full Text] [Related]
28. Role of different regions of alpha-synuclein in the assembly of fibrils.
Qin Z; Hu D; Han S; Hong DP; Fink AL
Biochemistry; 2007 Nov; 46(46):13322-30. PubMed ID: 17963364
[TBL] [Abstract][Full Text] [Related]
29. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease.
Ono K; Yoshiike Y; Takashima A; Hasegawa K; Naiki H; Yamada M
J Neurochem; 2003 Oct; 87(1):172-81. PubMed ID: 12969264
[TBL] [Abstract][Full Text] [Related]
30. Critical nucleus of Greek-key-like core of α-synuclein protofibril and its disruption by dopamine and norepinephrine.
Zou Y; Qian Z; Gong Y; Tang Y; Wei G; Zhang Q
Phys Chem Chem Phys; 2019 Dec; 22(1):203-211. PubMed ID: 31799519
[TBL] [Abstract][Full Text] [Related]
31. Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro.
Ono K; Hasegawa K; Yamada M; Naiki H
Biol Psychiatry; 2002 Nov; 52(9):880-6. PubMed ID: 12399141
[TBL] [Abstract][Full Text] [Related]
32. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.
Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R
J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420
[TBL] [Abstract][Full Text] [Related]
33. Monitoring the prevention of amyloid fibril formation by alpha-crystallin. Temperature dependence and the nature of the aggregating species.
Rekas A; Jankova L; Thorn DC; Cappai R; Carver JA
FEBS J; 2007 Dec; 274(24):6290-304. PubMed ID: 18005258
[TBL] [Abstract][Full Text] [Related]
34. Structural characterization of the intrinsically unfolded protein beta-synuclein, a natural negative regulator of alpha-synuclein aggregation.
Bertoncini CW; Rasia RM; Lamberto GR; Binolfi A; Zweckstetter M; Griesinger C; Fernandez CO
J Mol Biol; 2007 Sep; 372(3):708-22. PubMed ID: 17681539
[TBL] [Abstract][Full Text] [Related]
35. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein.
Heise H; Celej MS; Becker S; Riedel D; Pelah A; Kumar A; Jovin TM; Baldus M
J Mol Biol; 2008 Jul; 380(3):444-50. PubMed ID: 18539297
[TBL] [Abstract][Full Text] [Related]
36. Explorations of the application of cyanine dyes for quantitative alpha-synuclein detection.
Volkova KD; Kovalska VB; Segers-Nolten GM; Veldhuis G; Subramaniam V; Yarmoluk SM
Biotech Histochem; 2009 Apr; 84(2):55-61. PubMed ID: 19267288
[TBL] [Abstract][Full Text] [Related]
37. Assembly of alpha-synuclein fibrils in nanoscale studied by peptide truncation and AFM.
Zhang F; Lin XJ; Ji LN; Du HN; Tang L; He JH; Hu J; Hu HY
Biochem Biophys Res Commun; 2008 Apr; 368(2):388-94. PubMed ID: 18230346
[TBL] [Abstract][Full Text] [Related]
38. FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T.
Gerard M; Debyser Z; Desender L; Baert J; Brandt I; Baekelandt V; Engelborghs Y
J Neurochem; 2008 Jul; 106(1):121-33. PubMed ID: 18346205
[TBL] [Abstract][Full Text] [Related]
39. The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers.
Näsström T; Wahlberg T; Karlsson M; Nikolajeff F; Lannfelt L; Ingelsson M; Bergström J
Biochem Biophys Res Commun; 2009 Jan; 378(4):872-6. PubMed ID: 19070597
[TBL] [Abstract][Full Text] [Related]
40. [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl].
Pálfi M; Szökó E; Kálmán M
Orv Hetil; 2006 Jul; 147(27):1251-7. PubMed ID: 16927880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
